These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options. Piotrowska Z; Sequist LV Cancer J; 2015; 21(5):371-7. PubMed ID: 26389761 [TBL] [Abstract][Full Text] [Related]
17. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Ray M; Salgia R; Vokes EE Oncologist; 2009 Nov; 14(11):1116-30. PubMed ID: 19892771 [TBL] [Abstract][Full Text] [Related]
18. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Nakata A; Gotoh N Expert Opin Ther Targets; 2012 Aug; 16(8):771-81. PubMed ID: 22762482 [TBL] [Abstract][Full Text] [Related]
19. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392 [TBL] [Abstract][Full Text] [Related]
20. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]